|
🐜
|
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
17 auth.
C. K. Wibmer,
F. Ayres,
T. Hermanus,
Mashudu Madzivhandila,
Prudence Kgagudi,
B. Lambson,
M. Vermeulen,
Karin van den Berg,
T. Rossouw,
M. Boswell,
...
V. Ueckermann,
S. Meiring,
A. von Gottberg,
C. Cohen,
L. Morris,
J. Bhiman,
P. Moore
|
10 |
2021 |
10
🐜
|
|
🐜
|
The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection
12 auth.
E. Gray,
M. Madiga,
T. Hermanus,
P. Moore,
C. K. Wibmer,
Nancy L. Tumba,
...
L. Werner,
K. Mlisana,
S. Sibeko,
C. Williamson,
S. A. Abdool Karim,
L. Morris
|
8 |
2011 |
8
🐜
|
|
🐜
|
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape
22 auth.
P. Moore,
E. Gray,
C. K. Wibmer,
J. Bhiman,
M. Nonyane,
D. Sheward,
T. Hermanus,
Shringkhala Bajimaya,
Nancy L. Tumba,
-. Melissa,
...
Rose Abrahams,
B. Lambson,
N. Ranchobe,
Li‐hua Ping,
Nobubelo,
Ngandu,
Q. Karim,
S. Karim,
R. Swanstrom,
M. Seaman,
C. Williamson,
L. Morris
|
8 |
2012 |
8
🐜
|
|
🐜
|
Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop
16 auth.
P. Moore,
E. Gray,
D. Sheward,
M. Madiga,
N. Ranchobe,
Z. Lai,
W. Honnen,
M. Nonyane,
Nancy L. Tumba,
T. Hermanus,
...
S. Sibeko,
K. Mlisana,
S. A. Abdool Karim,
C. Williamson,
A. Pinter,
L. Morris
|
7 |
2011 |
7
🐜
|
|
🐜
|
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
28 auth.
S. Cele,
F. Karim,
G. Lustig,
J. E. San,
T. Hermanus,
H. Tegally,
J. Snyman,
T. Moyo-Gwete,
E. Wilkinson,
M. Bernstein,
K. Khan,
Shi-Hsia Hwa,
Sasha W. Tilles,
L. Singh,
J. Giandhari,
...
N. Mthabela,
M. Mazibuko,
Y. Ganga,
B. Gosnell,
S. A. Abdool Karim,
W. Hanekom,
W. V. Van Voorhis,
T. Ndung’u,
R. Lessells,
P. Moore,
M. S. Moosa,
Tulio de Oliveira,
A. Sigal
|
7 |
2022 |
7
🐜
|
|
🐜
|
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
58 auth.
Lingshu Wang,
T. Zhou,
Yi Zhang,
E. Yang,
Chaim A. Schramm,
W. Shi,
A. Pegu,
Olamide K. Oloniniyi,
Amy R. Henry,
S. Darko,
S. Narpala,
C. Hatcher,
David R. Martinez,
Y. Tsybovsky,
Emily Phung,
...
O. Abiona,
A. Antia,
Evan M. Cale,
Lauren A. Chang,
M. Choe,
Kizzmekia S. Corbett,
Rachel L. Davis,
Anthony T. DiPiazza,
Ingelise J. Gordon,
S. H. Hait,
T. Hermanus,
Prudence Kgagudi,
Farida Laboune,
K. Leung,
Tracy Liu,
R. Mason,
Alexandra F. Nazzari,
L. Novik,
S. O'connell,
S. O'dell,
A. Olia,
S. Schmidt,
T. Stephens,
Christopher D. Stringham,
C. A. Talana,
I-Ting Teng,
Danielle A. Wagner,
A. Widge,
Baoshan Zhang,
M. Roederer,
J. Ledgerwood,
T. Ruckwardt,
M. Gaudinski,
P. Moore,
N. Doria-Rose,
R. Baric,
B. Graham,
A. McDermott,
D. Douek,
P. Kwong,
J. Mascola,
N. Sullivan,
J. Misasi
|
7 |
2021 |
7
🐜
|
|
🐜
|
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
32 auth.
R. Keeton,
S. Richardson,
T. Moyo-Gwete,
T. Hermanus,
M. Tincho,
N. Benede,
N. Manamela,
R. Baguma,
Z. Makhado,
A. Ngomti,
T. Motlou,
M. Mennen,
Lionel R. Chinhoyi,
S. Skelem,
H. Maboreke,
...
D. Doolabh,
A. Iranzadeh,
A. Otter,
T. Brooks,
M. Noursadeghi,
J. Moon,
J. Blackburn,
N. Hsiao,
C. Williamson,
C. Riou,
A. Goga,
N. Garrett,
L. Bekker,
G. Gray,
N. Ntusi,
P. Moore,
W. Burgers
|
6 |
2021 |
6
🐜
|
|
🐜
|
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
38 auth.
S. Madhi,
A. Koen,
A. Izu,
L. Fairlie,
C. Cutland,
V. Baillie,
S. Padayachee,
K. Dheda,
S. Barnabas,
Q. Bhorat,
Carmen Briner,
P. Aley,
Sutika Bhikha,
T. Hermanus,
E. Horne,
...
A. Jose,
Prudence Kgagudi,
T. Lambe,
Masebole Masenya,
Mduduzi S. L. Masilela,
N. Mkhize,
A. Moultrie,
C. Mukendi,
T. Moyo-Gwete,
Amit J Nana,
A. Nzimande,
Faeezah Patel,
S. Rhead,
Carol Taoushanis,
Asha Thombrayil,
Samuel van Eck,
M. Voysey,
T. Villafana,
J. Vekemans,
S. Gilbert,
A. Pollard,
P. Moore,
G. Kwatra
|
6 |
2021 |
6
🐜
|
|
🐜
|
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
19 auth.
C. K. Wibmer,
F. Ayres,
T. Hermanus,
Mashudu Madzivhandila,
Prudence Kgagudi,
B. Oosthuysen,
B. Lambson,
Tulio de Oliveira,
Marion Vermeulen,
Karin van der Berg,
...
T. Rossouw,
M. Boswell,
V. Ueckermann,
S. Meiring,
A. von Gottberg,
C. Cohen,
L. Morris,
J. Bhiman,
P. Moore
|
6 |
2021 |
6
🐜
|
|
🐜
|
Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity
27 auth.
C. Riou,
R. Keeton,
T. Moyo-Gwete,
T. Hermanus,
Prudence Kgagudi,
R. Baguma,
Z. Valley-Omar,
Mikhail Smith,
H. Tegally,
D. Doolabh,
A. Iranzadeh,
L. Tyers,
Hygon Mutavhatsindi,
M. Tincho,
N. Benede,
...
G. Marais,
Lionel R. Chinhoyi,
M. Mennen,
S. Skelem,
E. du Bruyn,
C. Stek,
Tulio de Oliveira,
C. Williamson,
P. Moore,
R. Wilkinson,
N. Ntusi,
W. Burgers
|
6 |
2021 |
6
🐜
|
|
🐜
|
Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies
9 auth.
P. Moore,
D. Sheward,
M. Nonyane,
N. Ranchobe,
T. Hermanus,
E. Gray,
...
S. A. Abdool Karim,
C. Williamson,
L. Morris
|
6 |
2013 |
6
🐜
|
